|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Harpoon Therapeutics, Inc. (HARP) |
|
|
$0.89 0.00 (0.00%) as of 4:30 Fri 9/1
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
32,670,000 |
Market
Cap: |
29.20(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6295 - $1.06 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Harpoon Therapeutics is a clinical-stage immunotherapy company. Co.'s Tri-specific T cell Activating Construct (TriTACs) product candidates include: HPN328, which is for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217, which is for the treatment of multiple myeloma; and HPN536, which is for the treatment of ovarian and pancreatic cancers and other mesothelin- expressing solid tumors. Co.'s proprietary TriTAC product candidate is HPN601, which targets the epithelial cell adhesion molecule and is being developed for the treatment of multiple solid tumor indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
21,397,205 |
24,484,205 |
24,494,205 |
Total Buy Value |
$0 |
$492,135,715 |
$492,135,715 |
$502,135,715 |
Total People Bought |
0 |
1 |
3 |
3 |
Total Buy Transactions |
0 |
1 |
4 |
5 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Evnin Luke |
10% Owner |
|
2021-01-25 |
4 |
AS |
$21.23 |
$276,117 |
I/I |
(13,006) |
4,341,318 |
|
-24% |
|
Evnin Luke |
10% Owner |
|
2021-01-22 |
4 |
AS |
$21.72 |
$536,375 |
I/I |
(24,695) |
4,354,324 |
|
-4% |
|
Evnin Luke |
10% Owner |
|
2021-01-21 |
4 |
AS |
$22.11 |
$579,095 |
I/I |
(26,066) |
4,379,019 |
|
-6% |
|
Evnin Luke |
10% Owner |
|
2021-01-20 |
4 |
AS |
$0.00 |
$0 |
I/I |
(101,646) |
4,405,085 |
|
-14% |
|
Evnin Luke |
10% Owner |
|
2021-01-20 |
4 |
AS |
$23.95 |
$425,291 |
I/I |
(17,694) |
4,506,731 |
|
-14% |
|
New Leaf Bpo Management Ii, L.l.c |
10% Owner |
|
2021-01-11 |
4 |
B |
$17.00 |
$3,999,998 |
I/I |
235,294 |
913,860 |
1.5 |
-6% |
|
Hunt Ronald |
Director |
|
2021-01-11 |
4 |
B |
$17.00 |
$3,999,998 |
I/I |
235,294 |
913,860 |
2.25 |
-6% |
|
Wesche Holger |
Chief Scientific Officer |
|
2021-01-04 |
4 |
AS |
$17.32 |
$183,837 |
D/D |
(10,000) |
52,852 |
|
2% |
|
Wesche Holger |
Chief Scientific Officer |
|
2021-01-04 |
4 |
OE |
$0.60 |
$6,000 |
D/D |
10,000 |
62,852 |
|
- |
|
Wesche Holger |
Chief Scientific Officer |
|
2020-10-01 |
4 |
AS |
$16.19 |
$162,737 |
D/D |
(10,000) |
52,669 |
|
23% |
|
Wesche Holger |
Chief Scientific Officer |
|
2020-10-01 |
4 |
OE |
$0.60 |
$6,000 |
D/D |
10,000 |
62,669 |
|
- |
|
Erbez Georgia |
Chief Financial Officer |
|
2020-08-19 |
4 |
B |
$11.40 |
$57,000 |
I/I |
5,000 |
8,915 |
1.99 |
43% |
|
Erbez Georgia |
Chief Financial Officer |
|
2020-08-18 |
4 |
B |
$11.60 |
$24,337 |
I/I |
2,098 |
3,915 |
1.99 |
42% |
|
Erbez Georgia |
Chief Financial Officer |
|
2020-07-31 |
4 |
B |
$10.92 |
$19,842 |
I/I |
1,817 |
1,817 |
1.99 |
17% |
|
Wesche Holger |
Chief Scientific Officer |
|
2020-07-01 |
4 |
AS |
$16.20 |
$161,989 |
D/D |
(10,000) |
52,669 |
|
-7% |
|
Wesche Holger |
Chief Scientific Officer |
|
2020-07-01 |
4 |
OE |
$0.60 |
$6,000 |
D/D |
10,000 |
62,669 |
|
- |
|
Arix Bioscience Holdings Ltd |
10% Owner |
|
2020-05-28 |
4 |
S |
$21.33 |
$7,820,926 |
I/I |
(366,591) |
2,193,704 |
|
30% |
|
Arix Bioscience Holdings Ltd |
10% Owner |
|
2020-05-27 |
4 |
S |
$22.39 |
$270,144 |
I/I |
(12,064) |
2,560,295 |
|
28% |
|
Sacks Natalie |
Chief Medical Officer |
|
2020-05-18 |
4 |
AS |
$14.77 |
$22,479 |
D/D |
(1,522) |
45,754 |
|
13% |
|
Sacks Natalie |
Chief Medical Officer |
|
2020-05-18 |
4 |
OE |
$2.12 |
$3,227 |
D/D |
1,522 |
47,276 |
|
- |
|
Wesche Holger |
Chief Scientific Officer |
|
2020-05-12 |
4 |
AS |
$14.09 |
$19,720 |
D/D |
(1,400) |
52,669 |
|
22% |
|
Wesche Holger |
Chief Scientific Officer |
|
2020-05-12 |
4 |
OE |
$0.60 |
$840 |
D/D |
1,400 |
54,069 |
|
- |
|
Wesche Holger |
Chief Scientific Officer |
|
2020-05-11 |
4 |
AS |
$14.07 |
$14,065 |
D/D |
(1,000) |
52,669 |
|
24% |
|
Wesche Holger |
Chief Scientific Officer |
|
2020-05-11 |
4 |
OE |
$0.60 |
$600 |
D/D |
1,000 |
53,669 |
|
- |
|
Wesche Holger |
Chief Scientific Officer |
|
2020-05-08 |
4 |
AS |
$14.00 |
$14,000 |
D/D |
(1,000) |
52,669 |
|
37% |
|
213 Records found
|
|
Page 5 of 9 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|